Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:ANAC
CUSIP03242010
Phone+1-650-5437500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-92.08%
Return on Equity-133.71%
Return on Assets-38.09%
Miscellaneous
EmployeesN/A
Outstanding Shares44,860,000
Anacor Pharmaceuticals (NASDAQ:ANAC) Frequently Asked Questions
What is Anacor Pharmaceuticals' stock symbol?
Anacor Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANAC."
How were Anacor Pharmaceuticals' earnings last quarter?
Anacor Pharmaceuticals Inc (NASDAQ:ANAC) released its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.01. The biopharmaceutical company had revenue of $17.54 million for the quarter, compared to analyst estimates of $19.53 million. Anacor Pharmaceuticals had a negative return on equity of 133.71% and a negative net margin of 92.08%. The business's quarterly revenue was up 14.9% on a year-over-year basis. During the same period last year, the firm posted ($0.30) EPS. View Anacor Pharmaceuticals' Earnings History.
Has Anacor Pharmaceuticals been receiving favorable news coverage?
News stories about ANAC stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anacor Pharmaceuticals earned a news sentiment score of 0.10 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.33 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Anacor Pharmaceuticals?
Shares of ANAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anacor Pharmaceuticals' stock price today?
One share of ANAC stock can currently be purchased for approximately $99.20.
How big of a company is Anacor Pharmaceuticals?
Anacor Pharmaceuticals has a market capitalization of $4.50 billion.
How can I contact Anacor Pharmaceuticals?
Anacor Pharmaceuticals' mailing address is 1020 E Meadow Cir, PALO ALTO, CA 94303-4230, United States. The biopharmaceutical company can be reached via phone at +1-650-5437500.
MarketBeat Community Rating for Anacor Pharmaceuticals (ANAC)
MarketBeat's community ratings are surveys of what our community members think about Anacor Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
